INDIA – Drug major, Abbot, has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum hemorrhage (PPH).
PPH refers to excessive blood loss of 500 ml or more after vaginal delivery and 1,000 ml or more after a caesarean procedure, within 24 hours of childbirth. Although preventable, PPH is associated with almost 20 per cent maternal mortality in the country.
PPH, if left untreated, can result in complications like anaemia in the postpartum period or aggravate mental health problems including postnatal depression and post-traumatic stress disorder apart from other issues.
According to WHO, every year about 14 million women around the world suffer from PPH. 3 The risk of maternal mortality from hemorrhage is 1 in 1 000 deliveries in developing countries (100 per 100 000 live births).
The current prevention and treatment protocol for PPH requires cold-chain storage and distribution, as well as continual administration of medicines via intravenous drip infusion, Abbott said in a statement.
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, reported that the global market for Postpartum Hemorrhage (PPH) Treatment Devices is projected to grow at a 4% CAGR to reach US$427.9 Million by the end of 2026.
Amid the COVID-19 crisis, the global market for Postpartum Hemorrhage (PPH) Treatment Devices was estimated at US$726.4 Million in the year 2020.
Postpartum hemorrhage (PPH) accounts for majority of global maternal morbidity as well as mortality deaths. Emerging economies attributes for significantly higher number of causalities from obstetric hemorrhage as compared to developed countries.
The market growth is poised to be driven by increasing cases of pregnancy-related complications like multiple pregnancies, large size of baby and upturned uterus that considerably increase the risk of developing postpartum bleeding or hemorrhage.
The market is likely to also gain from increasing healthcare spending and ongoing efforts by various governments to raise awareness regarding these complications.
Abbott has launched this formulation for the private market under its own brand through an in-licensing and co-marketing agreement with Ferring Pharmaceuticals Pvt Ltd India (Ferring), a subsidiary of the Switzerland-based global biopharmaceuticals company.
“With the introduction of this room-temperature- stable carbetocin formulation in collaboration with Ferring, we are reiterating our commitment to improve maternal care, enabling both mothers and children to live through better health.
“This formulation has proven efficacy, a convenient formulation that addresses the needs for heat stability and can help with better health outcomes for mothers who just delivered a baby,” Abbott India Medical Director Srirupa Das said.